Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Català d’Oncologia Breast Cancer Observational Cohort Study DOI Open Access
Helena Pla, Bartomeu Fullana, Anna Esteve

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(8), P. 1366 - 1366

Published: April 19, 2025

Background/Objectives: Few large cohorts with relatively uniform treatment approaches and long-term follow-up are available for assessing clinical outcomes breast cancer (BC) patients. The Institut Català d’Oncologia (ICO) Breast Cancer Cohort was designed to well characterize patterns overall survival at 5 10 years, a particular focus on patients < 40 ≥70 years old, age groups often underrepresented in trials. Methods: In this retrospective, observational study, we included all pathologically confirmed invasive BC diagnosed treated between 2010 2014 ICO, Spanish reference center, until November 2023. We collected comprehensive real-world data clinicopathologic characteristics modalities. Overall (OS) estimated using the Kaplan–Meier technique reported stratified by prognostic factors of ≤40, 41–69 ≥70. Multivariate Cox model used estimate risk death subgroups age, adjusting subtype, stage grade. Results: Overall, 3451 I IV were treated, mean 58 (range 19–98); 371 (10.8%) ≤40 756 (21.9%) years. With 9.9 (SD = 3.5), 5- 10-year OS 89% (95% CI: 86–92%) 85% 81–88%) ≤ 40, respectively; those aged 91% 90–92%) 83–86%), 70% 66–73%) 50% 47–54%) respectively. relative (RS) 92% 88% 70 respectively, 82% 77% identified HR 4.90 3.44–6.97, p 0.001) ≥ compared 41 69 Conclusions: ICO Cohort, as far know, largest Spain follow-up, underscores critical role subtype determining cancer.

Language: Английский

Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review DOI Open Access
Javier Muñoz, Sabrina Nucera,

Natalia García

et al.

The Breast, Journal Year: 2025, Volume and Issue: unknown, P. 104465 - 104465

Published: April 1, 2025

We present the first documented oncologic case of a type I Kounis syndrome (KS) following paclitaxel administration, in very young patient with HER2-positive(+) early-stage breast cancer (BC). KS is relatively rare acute coronary triggered by anaphylactic or hypersensitivity reactions, which there limited awareness among healthcare providers. It subdivided four subtypes depending on cardiac artery medical history. While no established management guidelines exist, its treatment requires addressing severe infusion reactions while ensuring proper myocardial perfusion. hereby illustrate successful and report how tumor genomics through novel HER2DX assay helped re-defining entire neo/adjuvant strategy. integrates size nodal involvement 27 genes' expression data tracking biological BC-related immunologic signatures so to estimate prognostic predictive score. This demonstrates clinical genomic can be effectively integrated optimize therapeutic decisions HER2+ BC, offering model for personalized care also atypical complex cases.

Language: Английский

Citations

1
Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue DOI Creative Commons

Xiaoshuan Liang,

Yiwei Qin,

Pengwei Li

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2025, Volume and Issue: 17

Published: Jan. 1, 2025

Currently, female breast cancer (BC) represents the highest incidence of globally. This trend has raised significant attention regarding young women (BCYW). With advancements in treatment technology, BCYW survivors are living longer; however, risk developing or succumbing to a second primary (SPC) greatly increased. In addition, several factors, including age, menstrual cycle, hormonal changes, obesity, pregnancy, and breastfeeding, interact influence development SPC make its more difficult. study investigates relationship between SPC, focusing on morbidity trends, pathological genomics, recurrence rates, survival times, modalities, physiological fertility. Most involve BRCA pathogenic variants fall under triple-negative human epidermal growth factor receptor 2-overexpressing subtypes, increasing SPC. While there regional variations time following diagnosis an long-term outcomes remain unfavorable. choice for prolonged cumulative toxic effect. The combination endocrine therapy chemotherapy is effective treating BC, but it simultaneously increases specifically endometrial cancer. Furthermore, radiotherapy associated with heightened contralateral BC lung We aim address existing gaps literature enhance awareness risks BCYW, thereby offering valuable insights clinical treatment.

Language: Английский

Citations

0
Tamoxifen and Fertility in Women with Breast Cancer: A Systematic Review on Reproductive Outcomes and Oncological Safety of Treatment Interruption DOI Open Access
Mauro Francesco Pio Maiorano, Gennaro Cormio, Vera Loizzi

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(8), P. 3787 - 3787

Published: April 17, 2025

Breast cancer (BC) is the most prevalent malignancy among women worldwide, with a rising incidence in young, premenopausal patients. For those diagnosed hormone receptor-positive (HR+) BC, tamoxifen cornerstone of adjuvant endocrine therapy, significantly reducing recurrence risk and improving long-term survival. However, its prolonged use poses challenges for desiring pregnancy, prompting interest temporary treatment interruption as strategy to achieve reproductive goals while maintaining oncological safety. This systematic review evaluates impact on fertility, feasibility interruption, associated outcomes. Following Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) guidelines, we conducted comprehensive search across major databases, identifying three relevant studies, including one randomized controlled trial (RCT) two observational cohort studies. The findings suggest that allows successful pregnancies without increasing short-term rates. Notably, POSITIVE demonstrated pregnancy achievement rate 74% live birth 63.8%, comparable three-year disease-free survival between patients who interrupted continued therapy. concerns remain regarding tamoxifen’s teratogenic risks, emphasizing need strict contraceptive measures preconception counseling. Despite emerging evidence supporting this approach, safety data are limited. Further research warranted refine clinical recommendations optimize counseling young BC survivors.

Language: Английский

Citations

0
Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Català d’Oncologia Breast Cancer Observational Cohort Study DOI Open Access
Helena Pla, Bartomeu Fullana, Anna Esteve

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(8), P. 1366 - 1366

Published: April 19, 2025

Background/Objectives: Few large cohorts with relatively uniform treatment approaches and long-term follow-up are available for assessing clinical outcomes breast cancer (BC) patients. The Institut Català d’Oncologia (ICO) Breast Cancer Cohort was designed to well characterize patterns overall survival at 5 10 years, a particular focus on patients < 40 ≥70 years old, age groups often underrepresented in trials. Methods: In this retrospective, observational study, we included all pathologically confirmed invasive BC diagnosed treated between 2010 2014 ICO, Spanish reference center, until November 2023. We collected comprehensive real-world data clinicopathologic characteristics modalities. Overall (OS) estimated using the Kaplan–Meier technique reported stratified by prognostic factors of ≤40, 41–69 ≥70. Multivariate Cox model used estimate risk death subgroups age, adjusting subtype, stage grade. Results: Overall, 3451 I IV were treated, mean 58 (range 19–98); 371 (10.8%) ≤40 756 (21.9%) years. With 9.9 (SD = 3.5), 5- 10-year OS 89% (95% CI: 86–92%) 85% 81–88%) ≤ 40, respectively; those aged 91% 90–92%) 83–86%), 70% 66–73%) 50% 47–54%) respectively. relative (RS) 92% 88% 70 respectively, 82% 77% identified HR 4.90 3.44–6.97, p 0.001) ≥ compared 41 69 Conclusions: ICO Cohort, as far know, largest Spain follow-up, underscores critical role subtype determining cancer.

Language: Английский

Citations

0